What is Dexcom?
Dexcom, Inc. is a leading innovator in medical technology, specializing in the development and manufacturing of continuous glucose monitoring (CGM) systems. These advanced devices are designed to empower individuals with diabetes by providing real-time glucose data, thereby facilitating more effective health management. The company's core mission revolves around driving innovation, ensuring accuracy, and enhancing the quality of life for its users, all while making substantial advancements in the field of diabetes care globally. This focus on improving patient outcomes and technological sophistication positions Dexcom as a key entity in the health tech landscape.
How much funding has Dexcom raised?
Dexcom has raised a total of $457.7M across 5 funding rounds:
Series C
$30M
Series D
$22.5M
Stock Offering
$50.6M
Share Placement
$350M
Series B
$4.6M
Series C (2002): $30M with participation from RWI Investments, INVESCO, Windamere Venture Partners, Canaan Partners, Kauffman Fund, St. Paul Venture Capital, and Fog City Fund
Series D (2005): $22.5M led by Warburg Pincus, Canaan Partners, Fog City Fund, RWI Group, The Vertical Group, St. Paul Venture Capital, and Federated Kaufmann Fund
Stock Issuance/Offering (2005): $50.6M supported by Undisclosed
Share Placement (2017): $350M featuring Undisclosed
Series B (2020): $4.6M backed by Beta Bionics
Key Investors in Dexcom
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm renowned for its expertise in growth investing. Operating as a private partnership, the firm leverages decades of experience to support investors and management teams in building long-term, sustainable success across diverse market cycles.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
RWI Group
The RWI Team of certified ISO 9000 and TS 16949 experts provide Auditing, Systems Consulting, Training, and Quality Management / Engineering hands on help. Our methods have been built on Lean Manufacturing principles leading to effective improvements that impact goals for our Business and Manufacturing consulting clients.
What's next for Dexcom?
The substantial enterprise-level capital infusion, highlighted by the recent strategic investment, signals Dexcom's robust trajectory and its commitment to further innovation and market expansion. This backing is expected to fuel advancements in their CGM technology, potentially leading to enhanced product features, broader accessibility, and deeper integration into the healthcare ecosystem. The company's ongoing focus on improving diabetes management suggests future developments may include more sophisticated data analytics, predictive capabilities, and seamless connectivity with other health devices and platforms, solidifying its leadership in the medtech industry.
See full Dexcom company page
